News coverage about Xencor (NASDAQ:XNCR) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xencor earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.6214471220755 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Xencor (NASDAQ:XNCR) traded down $2.06 during midday trading on Wednesday, reaching $31.20. The company’s stock had a trading volume of 173,333 shares, compared to its average volume of 205,524. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $34.63.
Several equities research analysts have recently commented on XNCR shares. BidaskClub raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $37.00 price objective on shares of Xencor in a research note on Thursday, March 1st. Finally, Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Thursday, March 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $34.25.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.